Esperion Therapeutics Files Initial Public Offering For $150 Million
ANN ARBOR — The cholesterol-fighting drug developer Esperion Therapeutics Tuesday announced an initial public offering of $150 million of its common stock. Esperion also expects to grant the underwriters a 30-day option to purchase up to $22.5 million of additional shares of its common stock. The company said it would use the net proceeds of